Enzymology
Enzymatic cleavage of CD95 leaves tumor cells resistant to destruction
Published in Gene Therapy Weekly, July 8th, 2004
"The ability of tumor cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumor elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumor cells. We propose a new strategy by which tumor cells can resist CD95-induced apoptosis," scientists in Germany report.
"We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-07-08)
More Articles from Gene Therapy Weekly
- Bioengineering
Genetically modified mesenchymal stem cells act as cardiac pacemakers - Neuroscience
Gene knockdown ameliorates parkinsonian motor symptoms in study animals - Tumor Suppression
Repeated endostatin transfection extends the survival of fibrosarcoma models - Vector Development
Subterfuge enables gene therapy to cross the blood-brain barrier - Angiology
DDR1/DDR2 potential role in obstructive diseases of blood vessels and lungs - Bacteriology
B. henselae genotype I strains may be more pathogenic than type II strains - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
